

Product Information

Anti- GLP-1 (C-terminal)

produced in rabbit, affinity isolated antibody

Catalog Number **SAB4200642**

Product Description

Anti-GLP-1 (C-terminal) is produced in rabbit using as immunogen a synthetic peptide corresponding to the C-terminal region of human GLP1 (GeneID: 2641), conjugated to KLH. The corresponding sequence is identical in mouse and rat. The antibody is affinity-purified using the immunizing peptide immobilized on agarose.

Anti-GLP-1 (C-terminal) recognizes human GLP1. The antibody may be used in various immunochemical techniques including immunohistochemistry. Detection of the GLP1 (C-terminal) signal by immunohistochemistry is specifically inhibited by the immunizing peptide.

GLP-1 (Glucagon-like-peptide-1) is one of 8 peptide chains resulting from the pre-proglucagon cleavage, corresponding to amino acids 92-128. GLP-1 is involved in insulin secretion, glucose homeostasis, gastric emptying, intestinal growth, and regulation of food intake. GLP-1 is known to have the 'incretin effect' in response to nutrient ingestion. GLP-1 is secreted from intestinal L-cells, hindbrain, distal small bowel and colon and stimulates insulin secretion from the pancreas in a glucose-dependent fashion. GLP-1 possesses behavioral and physiological influence in regulation of food and drug reward, therefore GLP-1 is a favorable target for drug research. GLP-1 analogs such as Exendin 4 (EX4) and Liraglutide were approved for clinical use in type 2 diabetes (T2D).¹⁻⁴ GLP-1 was also reported to have neuroprotective role, in preclinical studies of Alzheimer's disease (AD), Parkinson's disease (PD), stroke and other neurodegenerative disorders. GLP-1 analogs cross the blood brain barrier and show impressive neuroprotective effects.⁴

Reagent

Supplied as a solution in 0.01 M phosphate buffered saline pH 7.4, containing 15 mM sodium azide as a preservative.

Antibody Concentration: ~ 1.0 mg/mL

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

For continuous use, store at 2–8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

Product Profile

Immunohistochemistry: a working concentration of 10-20 µg/mL is recommended using formalin-fixed, paraffin-embedded human pancreas sections.

Note: In order to obtain best results in different techniques and preparations we recommend determining optimal working concentration by titration test.

References

1. Skibicka, K.P., *Front. Neurosci.*, **7**, 181 (2013).
2. Stolar, M.W., et al., *Diabetes Metab. Syndr. Obes.*, **6**, 435-444, (2013).
3. Larsen, P.J., et al., *Curr. Pharm. Des.*, **9**, 1373-1382 (2003).
4. Holscher C., *J Endocrinol.*, 221, T31-41 (2014).

GG, AI,PHC 04/16-1